The biggest negative is that it is a completely new MOA. So we don't yet have proof of concept, which is a big hurdle to go on top of the standard drug development issues.
However, in the BIO database (as noted in #msg-77165730
), the probability of success in second indications—when PoC had presumably been established before any clinical trials—was lower
on average than the probability of success in primary indications, when PoC was typically not yet established except in preclinical models.